Showing results (111-120 of 156) with videos related to
Sort By:
Pageof 16
Haematologica|June 29, 2019
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trialsAlessandra Larocca, Roberto Mina, Massimo Offidani, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 30, 2013
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor RegistryRoberto Passera, Simona Pollichieni, Lucia Brunello, et al.Transplantation|November 19, 2016
Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease: An Italian Multicentric Retrospective Analysis on 94 Patients on Behalf of the Gruppo Italiano Trapianto di Midollo OsseoMichele Malagola, Valeria Cancelli, Cristina Skert, et al.Blood|August 13, 2011
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomideAlessandra Larocca, Federica Cavallo, Sara Bringhen, et al.Journal of Hematology & Oncology|January 11, 2019
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trialIlaria Saltarella, Fortunato Morabito, Nicola Giuliani, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2014
Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related deathPhilippe Moreau, Michele Cavo, Pieter Sonneveld, et al.Transplantation and Cellular Therapy|April 6, 2024
Evaluation of Circulating Endothelial Cells as Direct Marker of Endothelial Damage in Allo-Transplant Recipients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction SyndromeMirko Farina, Maria Chiara Scaini, Antonella Facchinetti, et al.Leukemia & Lymphoma|September 3, 2010
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myelomaMonika Engelhardt, Josefina Udi, Martina Kleber, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survivalAntonio Palumbo, Sara Bringhen, Alessandra Larocca, et al.Blood Advances|August 20, 2020
Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-CyJacopo Mariotti, Anna Maria Raiola, Andrea Evangelista, et al.Pageof 16